Outcome of male breast cancer: A matched single-institution series

Clinical Breast Cancer

Volumn 14, Issue 5, 2014, Pages 371-377

  Iorfida, Monica ^a   Bagnardi, Vincenzo ^a,b   Rotmensz, Nicole ^a   Munzone, Elisabetta ^a   Bonanni, Bernardo ^a   Viale, Giuseppe ^a,c   Pruneri, Giancarlo ^a,c   Mazza, Manuelita ^a   Cardillo, Anna ^a   Veronesi, Paolo ^a,c   Luini, Alberto ^a   Galimberti, Viviana ^a   Goldhirsch, Aron ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Counseling; Men; Prevention; Second primaries; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD EXAMINATION; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ECHOMAMMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALE BREAST CANCER; MAMMOGRAPHY; MASTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICAL EXAMINATION; BREAST NEOPLASMS, MALE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOTHERAPY; TREATMENT OUTCOME; TUMOR INVASION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS, MALE; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MASTECTOMY; MIDDLE AGED; NEOPLASM INVASIVENESS; RADIOTHERAPY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84922664337     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.02.008     Document Type: Article

References (36)

1. Anderson WF, Jatoi I, Tse J, Rosenbers PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 2010; 28:232-9.
2. Cutuli B, Le-Nir CC, Serin D, et al. Male breast cancer: evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol 2009; 73: 246-54.
3. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006; 367: 595-604.
4. Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist 2005; 10:471-9.
5. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002; 137:678-87.
6. Nahleh ZA, Srikantiah R, Safa M, et al. Male breast cancer in the Veterans Affairs population: a comparative analysis. Cancer 2007; 109:1471-7.
7. El-Tamer MB, Komenaka IK, Troxel A, et al. Men with breast cancer have better disease specific survival than women. Arch Surg 2004; 139:1079-82.
8. Marchal F, Salou M, Marchal C, et al. Men with breast cancer have same diseasespecific and event-free survival as women. Ann Surg Oncol 2009; 16:972-8.
9. Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004; 83:77-86.
10. Hill TD, Khamis HJ, Tyczynski JE, Berkel HJ. Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol 2005; 15:773-80.
11. Macdonald G, Paltiel C, Olivotto IA, Tyldesley S. A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer. Ann Oncol 2005; 16:1442-8.
12. Meijer-van Gelder ME, Look MP, Bolt-de Vries J, et al. Clinical relevance of biologic factors in male breast cancer. Breast Cancer Res Treat 2001; 68:249-60.
13. Boughey JC, Bedrosian I, Meric-Bernstam F, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 2006; 203:475-80.
14. Giordano SH, Cohen DS, Buzdar AU, et al. Breast cancer in men: a populationbased study. Cancer 2004; 101:51-7.
15. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101:736-50.
16. Ribeiro GG, Swindell R, Harris M, et al. A review of the management of the male breast carcinoma based on an analysis of 420 treated cases. Breast 1996; 5:141-6.
17. Miao H, Verkooijen HM, Chia KS, et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol 2011; 29:4381-6.
18. Chen X, Liu X, Zhang L, et al. Poorer survival of male breast cancer compared with female breast cancer patients may be due to biological differences. Jpn J Clin Oncol 2013; 43:954-63.
19. Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 1999; 85:629-39.
20. Lee UJ, Jones JS. Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening. Prostate Cancer Prostatic Dis 2009; 12:52-6.
21. Hemminki K, Scelo G, Boffetta P, et al. Second primary malignancies in patients with male breast cancer. Br J Cancer 2005; 92:1288-92.
22. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004; 22: 735-42.
23. Storm HH, Olsen J. Risk of breast cancer in offspring of male breast-cancer patients. Lancet 1999; 353:209.
24. Hultborn R, Hanson C, Kopf I, et al. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 1997; 17:4293-7.
25. Janssen-Heijnen MLG, Houterman S, Lemmens VEPP, Louwman MW, Maas HA, Coebergh JW. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 2005; 55: 231-40.
26. Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of nonesmall-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 2008; 26:54-9.
27. Gnerlich JL, Deshpande AD, Jeffe DB, et al. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in stage migration. Ann Surg Oncol 2011; 18:1837-44.
28. Andrykowski MA. Physical and mental health status and health behaviors in male breast cancer survivors: a national population-based, case-control study. Psychooncology 2012; 21:927-34.
29. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012; 62:10-29.
30. Kornegoor R, Verschuur-Maes AH, Buerger H, et al. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 2012; 25:398-404.
31. Ge Y, Sneige N, Eltorky MA, et al. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res 2009; 11:R28.
32. Sanchez-Munoz A, Roman-Jobacho A, Perez-Villa L, et al. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization. Oncology 2012; 83:228-33.
33. Muir D, Kanthan R, Kanthan SC. Male versus female breast cancers: a populationbased comparative immunohistochemical analysis. Arch Pathol Lab Med 2003; 127:36-41.
34. Rudlowski C, Friedrichs N, Faridi A, et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004; 84: 215-23.
35. Gómez-Raposo C, Zambrana Tévar F, Sereno Moyano M, et al. Male breast cancer. Cancer Treat Rev 2010; 36:451-7.
36. Johansson I, Nilsson C, Berglund P, et al. Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res 2012; 14:R31.